AgomAb Therapeutics NV

Contributing Author

Recent Articles by AgomAb Therapeutics NV

Apr-23	Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook AGMB GlobeNewswire
Mar-26	Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis AGMB -7.70% GlobeNewswire
Feb-09	Agomab Announces Closing of Initial Public Offering AGMB +6.55% GlobeNewswire
Feb-05	Agomab Announces Pricing of Initial Public Offering AGMB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information